Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study

The muscarinic receptor agonist xanomeline improved cognition in phase 2 trials in Alzheimer’s disease and schizophrenia. We present data on the effect of KarXT (xanomeline–trospium) on cognition in schizophrenia from the 5-week, randomised, double-blind, placebo-controlled EMERGENT-1 trial (NCT0369...

Descripción completa

Detalles Bibliográficos
Autores principales: Sauder, Colin, Allen, Luke A., Baker, Elizabeth, Miller, Andrew C., Paul, Steven M., Brannan, Stephen K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681874/
https://www.ncbi.nlm.nih.gov/pubmed/36414626
http://dx.doi.org/10.1038/s41398-022-02254-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681874/
https://www.ncbi.nlm.nih.gov/pubmed/36414626
http://dx.doi.org/10.1038/s41398-022-02254-9

Ejemplares similares